# INPLASY PROTOCOL

To cite: Gao et al. Aspirin Vs P2Y12 inhibitor monotherapy following dual antiplatelet therapy after coronary stenting in patients with ischemic heart disease: an updated systematic review and metaanalysis. Inplasy protocol 2022120011. doi: 10.37766/inplasy2022.12.0011

Received: 03 December 2022

Published: 03 December 2022

**Corresponding authors:** Yu Geng and Ping Zhang

gta03615@btch.edu.cn

zhpdoc@126.com

#### **Author Affiliation:**

Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.

Support: None.

Review Stage at time of this submission: Data analysis.

Conflicts of interest: None declared.

### INTRODUCTION

Review question / Objective: We sought to conduct a systematic review and metaanalysis to evaluate safety and

Aspirin Vs P2Y12 inhibitor monotherapy following dual antiplatelet therapy after coronary stenting in patients with ischemic heart disease: an updated systematic review and meta-analysis

Gao, T<sup>1</sup>; Wang, YT<sup>2</sup>; Meng, C<sup>3</sup>; Li, SY<sup>4</sup>; Bi, L<sup>5</sup>; Geng, Y<sup>6</sup>; Zhang, P<sup>7</sup>.

**Review question / Objective:** We sought to conduct a systematic review and meta-analysis to evaluate safety and effectiveness of aspirin or P2Y12 inhibitor monotherapy following dual antiplatelet therapy after percutaneous coronary intervention.

Condition being studied: Major adverse cardiac events, Cardio death, all-cause death, major bleeding, myocardial infarction, repeat revascularization, stent thrombosis and any stroke.

Information sources: We will search the references in the included trials and personal files. We will request advice from experts in the field. In addition, we will search associated articles from meetings, and contacted the authors of included trials, if need.

**INPLASY registration number:** This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 03 December 2022 and was last updated on 03 December 2022 (registration number INPLASY2022120011).

\*Tong Gao, Yintang Wang and Chang Meng have contributed equally to this work.

effectiveness of aspirin or P2Y12 inhibitor monotherapy following dual antiplatelet therapy after percutaneous coronary intervention. Condition being studied: Major adverse cardiac events, Cardio death, all-cause death, major bleeding, myocardial infarction, repeat revascularization, stent thrombosis and any stroke.

## **METHODS**

Participant or population: Patients with dual antiplatelet therapy after percutaneous coronary intervention for 12 months.

**Intervention:** Aspirin or P2Y12 inhibitor monotherapy.

**Comparator:** Aspirin or P2Y12 inhibitor monotherapy.

Study designs to be included: The search strategy was Prospective observational studies, RCTs were generally included.

Eligibility criteria: (1) Patients with dual antiplatelet therapy after percutaneous coronary intervention for 12 months. (2) treatment with aspirin or P2Y12 inhibitor monotherapy. (3) outcomes Indicators: Major adverse cardiac events, cardiac death, all-cause death, major bleeding, myocardial infarction, repeat revascularization, stent thrombosis and any stroke, including one.

Information sources: We will search the references in the included trials and personal files. We will request advice from experts in the field. In addition, we will search associated articles from meetings, and contacted the authors of included trials, if need.

Main outcome(s): Major adverse cardiac events, cardiac death, all-cause death, major bleeding, myocardial infarction, repeat revascularization, any stroke, et al.

Quality assessment / Risk of bias analysis: We evaluated the methodological quality of the individual studies using the Cochrane risk of bias tool for RCTs and using the Newcastle-Ottawa Scale for prospective observational studies. **Strategy of data synthesis:** We will consider using the number of participants and deaths between different groups for analysis. Mortality may also be reported.

Subgroup analysis: Subgroup analysis was performed on different kinds of P2Y12 inhibitor, follow up time or other.

Sensitivity analysis: We conducted sensitivity analyses to investigate the influence of a single study on the overall pooled estimate of each predefined outcome.

Country(ies) involved: China.

**Keywords:** Aspirin monotherapy, P2Y12 inhibitor Monotherapy, Dual Antiplatelet Therapy.

## **Contributions of each author:**

Author 1 - Tong Gao. Author 2 - Yintang Wang. Author 3 - Chang Meng. Author 4 - Siyuan Li. Author 5 - Lei Bi. Author 6 - Yu Geng. Email: gya02137@btch.edu.cn Author 7 - Ping Zhang. Email: zhpdoc@126.com